Drug data last refreshed 19m ago · AI intelligence enriched 1w ago
ADVIL (ibuprofen sodium) is an oral nonsteroidal anti-inflammatory drug (NSAID) approved in 2012 as a tablet formulation. It is used for the temporary relief of minor aches and pains due to headache, muscular aches, backache, minor arthritis pain, menstrual cramps, and the common cold. Ibuprofen sodium works by inhibiting prostaglandin synthesis to reduce inflammation and pain.
Peak-stage OTC NSAID with moderate competitive pressure (30/100) indicates mature brand requiring defensive marketing and operational efficiency focus.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Bioequivalence of a Fixed Dose Combination Tablet Containing 400 mg Ibuprofen and 60 mg Pseudoephedrine-HCl Compared to Two Film Coated Fixed Dose Combination Tablets RhinAdvil(R)(200 mg Ibuprofen and 30 mg Pseudoephedrine-HCl) Administered in Healthy Subjects
Ibuprofen Sodium Tension Headache Study
Bioequivalence of a Fixed Dose Combination Tablet Containing 200 mg Ibuprofen and 30 mg Pseudoephedrine-HCl Compared to RhinAdvil(R)(200 mg Ibuprofen and 30 mg Pseudoephedrine-HCl) as a Fixed Dose Combination Tablet Administered in Healthy Volunteers.
Worked on ADVIL at GSK? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
ADVIL careers focus on defensive brand management, retailer partnerships, and consumer marketing in a mature OTC market with high generic competition. Roles emphasize market share maintenance, promotional strategy, and supply chain efficiency rather than clinical innovation or launch execution.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo